Accurate prediction of human pharmacokinetics is critical for drug development—especially for low-clearance compounds that challenge conventional in vitro models. This case study demonstrates how cryopreserved plateable human hepatocytes overcome the limitations of short-duration assays by maintaining metabolic activity over extended incubations (up to 72 hours).

Highlights

• Overcome Traditional Barriers: Reliably assess low-turnover compounds that typically escape accurate clearance measurement.
• Improved Predictability: Generate robust intrinsic clearance data to enhance human PK predictions and reduce translational risk.
• Smarter Early Decisions: Enable confident candidate selection and accelerate development for slowly metabolized drugs.

Download the full case study to see how this validated approach can help you de-risk low-clearance candidates and move forward with greater confidence.